Solid Biosciences Advances SGT-003 DMD Gene Therapy with FDA Alignment, Reports No Liver Toxicity
Mar 12, 2026
Solid Biosciences has secured FDA alignment on a registration pathway for its Duchenne muscular dystrophy gene therapy SGT-003, with 36 patients dosed to date showing no drug-induced liver injury, myocarditis, or other serious adverse events reported with competing therapies.